Fulcrum Asset Management LLP Purchases 18,554 Shares of Moderna, Inc. $MRNA

Fulcrum Asset Management LLP acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 18,554 shares of the company's stock, valued at approximately $3,775,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC boosted its stake in shares of Moderna by 21.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 28,339 shares of the company's stock valued at $5,354,000 after purchasing an additional 5,065 shares in the last quarter. Brighton Jones LLC bought a new position in shares of Moderna during the third quarter valued at $496,000. Candriam S.C.A. lifted its holdings in shares of Moderna by 24.5% during the third quarter. Candriam S.C.A. now owns 384,828 shares of the company's stock worth $74,377,000 after purchasing an additional 75,632 shares during the period. Ethic Inc. lifted its holdings in shares of Moderna by 23.6% during the third quarter. Ethic Inc. now owns 19,394 shares of the company's stock worth $3,735,000 after purchasing an additional 3,700 shares during the period. Finally, Parallel Advisors LLC grew its stake in shares of Moderna by 8.8% in the third quarter. Parallel Advisors LLC now owns 5,082 shares of the company's stock worth $979,000 after purchasing an additional 410 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Raised outlook and improved results: Moderna lifted its 2026 revenue-growth forecast to 15%–25% after a Q3 beat, citing lower costs and gains from respiratory vaccines. Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
• Positive Sentiment: Oncology pipeline milestone: Phase 3 data for personalized cancer therapy intismeran showed a 42% reduction in melanoma recurrence or death risk. Moderna aims to file with the FDA by year-end 2026, potentially setting up a decision in 2027. Can Moderna's First Cancer Therapy Win FDA Approval in 2027?
• Positive Sentiment: Moderna’s collaboration with Tempus AI is among partnerships expected to generate about $192.5 million over five years, adding a potential source of revenue beyond vaccine sales. The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
• Neutral Sentiment: Analysts raised one fair-value estimate from $135.84 to $145.42, reflecting improved Q3 execution and intismeran’s potential, while noting uncertainty about future COVID and oncology revenue. Moderna Stock Fair Value Rises After Intismeran Data And Q3 Beat
• Negative Sentiment: Revenue concentration and valuation risk: Nearly all revenue still comes from COVID-related products, leaving Moderna exposed to demand changes. Goldman Sachs raised its target to $195 but kept a neutral rating; that target and the cited fair-value estimate are both below the $269 price in the provided market data. Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy

Insider Buying and Selling

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares in the company, valued at approximately $10,374,353.55. This represents a 4.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of the firm's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the sale, the president directly owned 1,636,565 shares of the company's stock, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 197,251 shares of company stock valued at $33,875,904 over the last 90 days. Company insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. Sanford C. Bernstein restated a "market perform" rating on shares of Moderna in a report on Friday, September 25th. Berenberg Bank lifted their target price on Moderna from $45.00 to $100.00 and gave the stock a "hold" rating in a report on Friday, September 11th. Rothschild & Co Redburn cut Moderna from a "neutral" rating to a "sell" rating and increased their price target for the company from $40.00 to $81.00 in a research note on Thursday, September 3rd. Jefferies Financial Group restated a "hold" rating and set a $150.00 price objective (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Finally, Brookline Capital Markets restated a "buy" rating on shares of Moderna in a research report on Wednesday, August 19th. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $113.75.

Moderna Trading Up 5.8%

Shares of MRNA opened at $269.00 on Tuesday. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. The firm's fifty day simple moving average is $194.47 and its two-hundred day simple moving average is $92.61. Moderna, Inc. has a 12 month low of $22.28 and a 12 month high of $280.80.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, topping analysts' consensus estimates of ($1.10) by $1.48. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. During the same period last year, the business posted ($0.51) EPS. The business's revenue was up 29.2% compared to the same quarter last year. Equities analysts expect that Moderna, Inc. will post -6.11 earnings per share for the current year.

Moderna Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company's commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.